New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 15, 2012
18:04 EDTRDUSRadius Health withdraws registration statement on form S-1
In a regulatory filing Radius said: Radius Healtth hereby applies for withdrawal of the company’s registration statement on Form S-1 filed with the Securities and Exchange Commission on February 6, 2012 and amended on September 28, October 19 and November 7. Pursuant to Rule 477 under the Securities Act of 1933, as amended the company is withdrawing the Registration Statement, which has not been declared effective, because the proposed public offering under the Registration Statement was abandoned due to general market conditions. Since the Registration Statement was not declared effective by the Commission, no shares of common stock as described in the Registration Statement were sold. In addition, the Company hereby applies for withdrawal of the Company’s Registration Statement on Form 8-A, filed with the Commission on November 5.
News For RDUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2015
08:12 EDTRDUSRadius Health shares can still reach $85, says Cantor
After Radius announced that it would delay filing for FDA approval of its abaloparatide drug by one quarter, Cantor thinks the decline in the stock was "excessive." The firm still believes that the drug's commercial opportunity along with the impact of other drugs from its pipeline, can drive the stock to $85. Cantor keeps an $85 price target and Buy rating on the shares.
November 17, 2015
08:34 EDTRDUSRadius Health submits MAA for abaloparatide
Radius Health announced that it has submitted a Marketing Authorization Application, or MAA, for an investigational, once-daily subcutaneous injection of abaloparatide, a novel synthetic peptide. In addition to other data, the MAA is supported by clinical studies exploring the use of abaloparatide for the treatment of women with postmenopausal osteoporosis, including the pivotal 18-month ACTIVE study which enrolled 2463 women. The announcement is being made during the company's Investor Day meeting being held today in New York City.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use